3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
63
Ovarian Neoplasms
8
Neoplasm Metastasis
8
Endometrial Neoplasms
6
Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Hereditary Sensory and Autonomic Neuropathies
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Breast Diseases
3
Small Cell Lung Carcinoma
2
Melanoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Head and Neck Neoplasms
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Salivary Gland Neoplasms
1
Recurrence
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Locoregional Recurrence
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
Docetaxel
6
avelumab
5
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Fulvestrant
×
90 days
×
Clear all
No trials found.